Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth
Cancer Research and Treatment. 2018;50(3):1009-1022 
EXTH-73. A NOVEL ANTI-GALECTIN-3 MONOCLONAL ANTIBODY THERAPEUTIC DIMINISHES MIGRATION AND SLOWS TUMOR GROWTH TO PROLONG SURVIVAL IN GLIOBLASTOMA
Neuro-Oncology. 2022;24(Supplement_7):vii226-vii226
A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth
IUBMB Life. 2012;64(9):757-765
EXTH-67. THERAPEUTIC EFFICACY OF GC1118, A NOVEL ANTI-EGFR ANTIBODY, AGAINST GLIOBLASTOMA WITH HIGH EGFR AMPLIFICATION IN PATIENT-DERIVED XENOGRAFTS
Neuro-Oncology. 2021;23(Supplement_6):vi178-vi178
25. Genetically Modified T Cells Directed to Glioblastoma Suppress Tumor Growth in a Rodent Glioma Model
Molecular Therapy. 2011;19:S10
Targeting ERBB2 overcomes resistance to the anti-EGFR therapeutic antibody cetuximab
Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies. 2023;75-81
Interferon as an Antiviral and Anti-tumor Therapeutic Agent
Ophthalmology. 1980;87(12):1236-1238
532. Neuropilin-1 Expressing Mononuclear Cells (NEMs), a Novel Population of Bone Marrow Cells Recruited by AAV2-Sema3A, Contributes to Vessel Normalization and Inhibits Tumor Growth
Molecular Therapy. 2011;19:S204
CT16: A dual antibody targeting both EGFR and Notch suppresses EGFR blockage and radiation resistance by decreasing tumor-initiating cell frequency
Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies. 2023;83-89
EXTH-19. EVALUATING THE ANTI-TUMOR EFFECT OF A NOVEL THERAPEUTIC AGENT, MAGMAS INHIBITOR, IN MALIGNANT GLIOMA
Neuro-Oncology. 2020;22(Supplement_2):ii90-ii91